Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)Loretta J. Nastoupil, Christopher R. Flowers, Thomas M. Habermann et al.|Blood|2023Cited by 7
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell LymphomaLoretta J. Nastoupil, Christopher R. Flowers, Clark R. Andersen et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 6